Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (192 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.2% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: onsethypertensionassessdiagnosisdefined
  Phrases that lowered it: painupperefficacyaminotransferasepharmacokinetics
• Has a data monitoring committee: not given (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 514 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 303 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Sex: female (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia NCT02059135 · started 2014 · scored riskier than 59% of active trials completed
• KW-3357 Study in Patients With Early Onset Severe Preeclampsia NCT04182373 · started 2019 · scored riskier than 25% of active trials completed
• Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial) NCT03213639 · started 2018 · scored riskier than 20% of active trials completed
• The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine NCT02558023 · started 2015 · scored riskier than 49% of active trials terminated
• Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia NCT01095939 · started 2010 · scored riskier than 20% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.